Abstract
Adenosine A2A receptors are members of the G protein-coupled receptor family and mediate multiple physiological effects of adenosine, both at the central nervous system (CNS) and at peripheral tissues, by activating several pathways or interacting with other receptors or proteins. Increasing evidence relate A2A receptors with pharmacological stress testing, neurodegenerative disorders (such as Parkinsons disease) and inflammation, renewing the interest in these receptors, increasingly viewed as promising therapeutic targets. Series of agonists and antagonists have been developed by medicinal chemistry artwork either by structure activity relationship (SAR) or quantitative structure activity relationship (QSAR) studies. These studies have allowed identification of the structural and electrostatic requirements for high affinity A2A receptor binding and, therefore, contributing to the rational design of A2A receptor ligands. Additional rational chemical modifications of the existing A2A receptor ligands may further improve their affinity/selectivity. The purpose of this review is to analize and summarize aspects related to the medicinal chemistry of A2A receptor ligands, their present and potencial therapeutic applications by exploring the molecular structure and physiological and pathophysiological roles of A2A receptors.
Keywords: A2A receptor ligands, modified nucleosides, modified purines, other heterocycles, synthetic strategies, A2A receptor antagonists, A2A receptor agonists
Current Pharmaceutical Design
Title: Ligands and Therapeutic Perspectives of Adenosine A2A Receptors
Volume: 14 Issue: 17
Author(s): C. Diniz, F. Borges, L. Santana, E. Uriarte, J. M.A. Oliveira, J. Goncalves and P. Fresco
Affiliation:
Keywords: A2A receptor ligands, modified nucleosides, modified purines, other heterocycles, synthetic strategies, A2A receptor antagonists, A2A receptor agonists
Abstract: Adenosine A2A receptors are members of the G protein-coupled receptor family and mediate multiple physiological effects of adenosine, both at the central nervous system (CNS) and at peripheral tissues, by activating several pathways or interacting with other receptors or proteins. Increasing evidence relate A2A receptors with pharmacological stress testing, neurodegenerative disorders (such as Parkinsons disease) and inflammation, renewing the interest in these receptors, increasingly viewed as promising therapeutic targets. Series of agonists and antagonists have been developed by medicinal chemistry artwork either by structure activity relationship (SAR) or quantitative structure activity relationship (QSAR) studies. These studies have allowed identification of the structural and electrostatic requirements for high affinity A2A receptor binding and, therefore, contributing to the rational design of A2A receptor ligands. Additional rational chemical modifications of the existing A2A receptor ligands may further improve their affinity/selectivity. The purpose of this review is to analize and summarize aspects related to the medicinal chemistry of A2A receptor ligands, their present and potencial therapeutic applications by exploring the molecular structure and physiological and pathophysiological roles of A2A receptors.
Export Options
About this article
Cite this article as:
Diniz C., Borges F., Santana L., Uriarte E., Oliveira M.A. J., Goncalves J. and Fresco P., Ligands and Therapeutic Perspectives of Adenosine A2A Receptors, Current Pharmaceutical Design 2008; 14 (17) . https://dx.doi.org/10.2174/138161208784746842
DOI https://dx.doi.org/10.2174/138161208784746842 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Progresses in Application of Fullerenes in Cosmetics
Recent Patents on Biotechnology Current Advances in L-DOPA and DOPA-Peptidomimetics: Chemistry, Applications and Biological Activity
Current Medicinal Chemistry Obesity Pharmacotherapy: Current Perspectives and Future Directions
Current Cardiology Reviews RNA Interference (RNAi) Patents and Human Health Related Applications of RNAi
Recent Patents on DNA & Gene Sequences Evaluation and Prediction of Early Alzheimer’s Disease Using a Machine Learning-based Optimized Combination-Feature Set on Gray Matter Volume and Quantitative Susceptibility Mapping
Current Alzheimer Research BACE1 Deficient Mice: Their Role in Drug Target Validation and Implications for Alzheimers Disease Therapies
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Mitochondrial Targeting for Development of Novel Drug Strategies in Brain Injury
Central Nervous System Agents in Medicinal Chemistry A1 Receptors Ligands: Past, Present and Future Trends
Current Topics in Medicinal Chemistry Cucurbitacin E, An Experimental Lead Triterpenoid with Anticancer, Immunomodulatory and Novel Effects Against Degenerative Diseases. A Mini-Review
Current Topics in Medicinal Chemistry Protein Conformational Misfolding and Amyloid Formation: Characteristics of a New Class of Disorders that Include Alzheimers and Prion Diseases
Current Medicinal Chemistry The Alzheimer Pandemic: Is Paracetamol to Blame?
Inflammation & Allergy - Drug Targets (Discontinued) Alcohol Abuse and HIV Infection: Role of DRD2
Current HIV Research Genetics of the First Seven Proprotein Convertase Enzymes in Health and Disease
Current Genomics NSAID Use and the Risk of Parkinsons Disease
Current Drug Safety Therapeutic Approaches to Polyglutamine Diseases: Combating Protein Misfolding and Aggregation
Current Pharmaceutical Design The Role of Minocycline in Ischemia-Reperfusion Injury: A Comprehensive Review of an Old Drug with New Implications
Recent Patents on Cardiovascular Drug Discovery PET Radiotracers for Molecular Imaging in Dementia
Current Radiopharmaceuticals P2Y Receptors in the Mammalian Nervous System: Pharmacology, Ligands and Therapeutic Potential
CNS & Neurological Disorders - Drug Targets Targeting Neurotrophin Receptors in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Identification and Characterization of Follistatin-Related Protein-1 Involved in the Regulation of Chinese Perch Skeletal Muscle Hyperplasia
Current Molecular Medicine